Correction: Assessment of plasma lyso-Gb<sub>3</sub> for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.

Correction: Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.

Bichet, Daniel G; Aerts, Johannes M; Auray-Blais, Christiane; Maruyama, Hiroki; Mehta, Atul B; Skuban, Nina; Krusinska, Eva; Schiffmann, Raphael.

Afiliação

Bichet DG; Department of Medicine, Hôpital du Sacré Coeur, University of Montréal, Montréal, QC, Canada.
Aerts JM; Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, Netherlands.
Auray-Blais C; Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada.
Maruyama H; Department of Clinical Nephroscience, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Mehta AB; Lysosomal Storage Disorders Unit, University College London, London, UK.
Skuban N; Amicus Therapeutics, Cranbury, NJ, USA.
Krusinska E; Amicus Therapeutics, Cranbury, NJ, USA.
Schiffmann R; Baylor Scott & White Research Institute, Dallas, TX, USA. Raphael.Schiffmann@BSWHealth.org.

Genet Med ; 23(1): 238, 2021 Jan.

Article em En | MEDLINE | ID: mdl-33219325

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article